Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 224 results for "Tecfidera Treated Patients"

New Biogen MS drug challenges Copaxone

Over Half of Audited Multiple Sclerosis Patients Currently Tre...

BURLINGTON, Mass. , July 22,2014 /PRNewswire/ --Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing ... OSIX News, 1 month ago

1 images for "Tecfidera Treated Patients"

ABC News 4 Charleston, 1 month ago

New oral MS treatment Tecfidera approved for use in England and Wales

Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in England and Wales, the National Institute for Health and Care Excellence (NICE) has announced. The NHS must now begin funding this treatment for eligible ...
 Multiple Sclerosis Society6 days ago MS pill Tecfidera available on NHS in England and Wales  Noodls1 month ago

Report: Over Half of MS Patients Treated With Tecfidera Have Experienced Minor Side Effects

News Categories Clinical Trials Research News Industry Trends Agency
 Pharmscope1 month ago

TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta

MISSISSAUGA, ON, Aug. 7, 2014 /CNW/ -Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERA (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERA is a first-line oral treatment for adults with ...
 MoneyShow.com3 weeks ago TECFIDERA(tm), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed  Finwin3 weeks ago

Obamacare drug benefits block access to vital medicines

[description]Many ACA plans have closed drug formularies that exclude some drugs to treat chronic diseases, saddling patients with the full cost of these medications.[/description ] An estimated eight million people have signed up for health care ...
 World Socialist Web Site1 month ago
Boston Globe

FDA okays Genzyme pill for Gaucher disease

Federal regulators Tuesday okayed for US sale a Genzyme experimental capsule that could become the top-selling pill to treat the rare genetic disorder Gaucher disease. Food and Drug Administration approval of the drug candidate, called Cerdelga, ...
 Boston Globe1 week ago
Boston Globe

FDA approves new injectable multiple sclerosis treatment from Cambridge's Biogen Idec

Scrambling to stay ahead of the competition in bringing multiple sclerosis drugs to market, Biogen Idec Inc. won US regulatory approval Friday to sell a new type of injectable drug that treats adults with the most common form of the ...
 Boston Globe2 weeks ago Company Update: Biogen Idec Inc (NASDAQ:BIIB) Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub  Jutia Group1 week ago Biogen Idec finally gets approval for MS drug Plegridy  Examiner.com2 weeks ago Market Update: Biogen Idec Inc (NASDAQ:BIIB) Biogen wins U.S. approval of long acting multiple sclerosis drug  Jutia Group2 weeks ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency3 weeks ago
Motley Fool

Biogen Stock's Tecfidera Embarrasses Wall Street

It's hard to imagine that Biogen Idec (NASDAQ: BIIB Tecfidera was the third oral MS drug to get the FDA green-light when it was approved in March 2013, but while Novartis (NYSE: NVS Another great quarter Biogen's second quarter sales jumped 40% ...
 Motley Fool1 month ago NICE Gives Nod to Biogen Idec's MS Drug Tecfidera  FDA News1 month ago US FDA approves Biogen's MS drug  Bio Spectrum Asia1 week ago
Pharma Letter

NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)

In final guidance, the National Institute for Health and Care Excellence (NICE) has recommended the use of Biogen Idec's multiple sclerosis drug, dimethyl fumarate (also called Tecfidera). The NHS now has a legal obligation to begin funding ...
 FirstWord Pharma5 days ago NICE issues positive draft FAD guidance on Tecfidera11-07-2014  Pharma Letter1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less